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Available online 26 November 2012AbstractAcute psychosis after corticosteroid treatment is not unusual; however, the induction of psychosis by a low dose of corticosteroid is
uncommon. We describe the case of a 77-year-old man who had adrenal insufficiency and Hashimoto’s thyroiditis who, with previous corti-
costeroid exposure, developed insomnia, sexual hallucinations, aggression and exhibited self-harm behavior after the administration of cortisone
25 mg in the morning and 12.5 mg in the evening. These psychiatric symptoms improved when the corticosteroid therapy was discontinued, but
recurred after re-administering 5 mg prednisolone per day. Agitation persisted even at a very low dose of prednisolone, namely 2.5 mg per day.
He recovered after corticosteroid treatment was stopped.
Copyright  2012, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Corticosteroids are used to treat many different medical
conditions. The systemic side-effects include weight gain,
infection, diabetes, hypertension, osteoporosis, peptic ulcera-
tion, and Cushingoid features, and are well known.1 Mental
changes in patients are not uncommon after corticosteroid use.
Steroid psychosis-related symptoms include depression,
mania, psychosis, and delirium.2 High doses of corticosteroid,
namely more than 40 mg of prednisolone per day, are more
likely to cause the development of steroid psychosis.3 None-
theless, doses of corticosteroid as low as 5 mg or even 2.5 mg
prednisolone daily have been known to induce psychosis.4e6
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A 77-year-old male had suffered from weakness for 3 days.
On arrival at the emergency department (ED), his body
temperature was 35.4C. His other vital signs were normal.
The patient’s level of consciousness was normal and no other
physical examinations were remarkable. When the patient’s
history was reviewed, it was found that he was hypertensive
and had atrial fibrillation.
Two-and-a-half months earlier, he had fallen outside and
had arrived at our ED by ambulance, where he had presented
with a slow response and multiple abrasions on his legs. A
finger stick test gave a reading of 107 mg/dL. Blood tests only
showed hyponatremia with a serum sodium level of 108 meq/
L. A head computed tomography (CT) scan revealed only
brain atrophy. Subsequent endocrine tests demonstrated he had
adrenal insufficiency and hypothyroidism. The laboratory
results are shown in Table 1. He was treated with cortisone
25 mg in the morning, 12.5 mg in the evening and thyroxine
50 mg in the morning. He also received a 3-day course of 3%
saline infusion and a subsequent 3-day course of normal saline
infusion. He was discharged with normal consciousness and
a serum sodium level of 131 meq/L. Three days later heMedicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Laboratory data.
Reference range 2.5 M before 2nd ED visit 3rd ED visit 4th ED visit
Hemoglobin (g/dL) 13.0e18.0 12.5 13.8 13.3
White-cell count (per m3) 3800e10,000 6000 4800 4900 4700
Differential count (%)
Neutrophils 37.0e75.0 64.0 49.3 44.9 57.5
Lymphocytes 20.0e55.0 17.0 27.3 32.0 29.2
Monocytes 4.0e10.0 13.0 17.4 17.4 11.0
Eosinophils 0.0e5.0 3.0 5.8 5.3 1.9
Basophils 0.0e2.0 0.0 0.2 0.4 0.4
Glucose (mg/dl) 70e110 90 d d 100
AST (U/L) 5e35 28 41 30 24
BUN (mg/dL) 8e20 5 7 16 d
Creatinine (mg/dL) 0.5e1.3 0.9 0.7 0.8 0.7
Sodium (meq/L) 133e145 108 115 131 136
Potassium (meq/L) 3.3e5.1 4.3 4.0 4.2 3.7
Calcium ion (mg/dL) 3.68e5.60 d 4.42 d 4.69
Calcium (mg/dL) 8.40e10.20 d d 9.3 d
Ammonia (ug/dL) d d d 40 d
TSH (uIU/mL) 0.27e4.20 27.53 33.01 d 29.53
Free T4 (ng/dL) 0.93e1.70 0.38 d d 0.88
Cortisol (ug/dL) AM 6.2e19.4 AM 0.2 PM 0.4 d d
PM 2.3e11.9




AST ¼ aspartate transaminase; BUN ¼ blood urea nitrogen; RIA ¼ radioimmunoassay; TSH ¼ thyroid-stimulating hormone.
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lent to 50 mg of cortisone) in the morning, 5 mg in the
evening, and thyroxine 100 mg in the morning from our
endocrine outpatient clinic and he was lost to follow-up after
this.
This time (his second presentation at the ED) his blood tests
showed hyponatremia with a serum sodium level of 115 meq/L,
a low serum cortisol level and a high serum thyroid-stimulating
hormone level (Table 1). Ten hours later he left against medical
advice after receiving medication including cortisone 50 mg in
the morning, cortisone 25 mg and thyroxine 100 mg in the
evening. Three days later he visited our endocrine outpatient
clinic. His symptoms had improved and his medication was
adjusted to cortisone 25 mg in the morning, 12.5 mg in the
evening and thyroxine 100 mg in the morning.
On the day 6, he returned to the ED for a third time
suffering from insomnia, bizarre speech, and unusual behavior
that had lasted for 2 days. He had also suffered from diarrhea 3
days earlier, but this had improved. His vital signs were
normal, except for a blood pressure of 160/72 mmHg and the
fact that he was delirious; his other physical examination
results were normal. A finger stick test gave a result of 96 mg/
dl and his serum sodium was 131 meq/L. His other laboratory
results are shown in Table 1. A head CT scan showed no
change compared to his previous CT. An adrenal crisis was
suspected and he received 100 mg intravenous hydrocortisone.
He remained delirious and therefore received an increased
dose of cortisone (50 mg in the morning and 25 mg in the
evening). His thyroxine was maintained. He was discharged
13 hours later, again against medical advice.On day 7 he visited our ED for a fourth time, this time
showing symptoms of insomnia, sexual hallucinations,
aggression and self-harm behavior. He was also disoriented
and agitated. His serum glucose and sodium were normal. He
was sedated with intravenous midazolam. On day 8, a diag-
nosis of acute psychosis was made, therefore the corticosteroid
treatment was stopped and he received olanzapine 5 mg stat
and at night. On day 9, based on results indicating positive
anti-microsomal antibody titer and anti-thyroglobulin antibody
titer levels (Table 1), he was diagnosed with hypothyroidism
due to Hashimoto’s thyroiditis. On day 10, a brain magnetic
resonance image (MRI) showed only brain atrophy. He then
began to receive olanzapine 5 mg twice a day. He became
calm, but still had hallucinations. On day 12, an electroen-
cephalogram (EEG) revealed moderately diffuse encephalop-
athy. At this point, we re-administered prednisolone (2.5 mg in
the morning and 2.5 mg at night) and adjusted the olanzapine
dose to 5 mg at night because he had become mildly lethargic.
On day 13 he became agitated, so we tapered off his pred-
nisolone to a dose of 2.5 mg daily on day 14. On day 15 we
stopped the steroid use completely again due to persistent
hyperactivity and sleeplessness. On day 16 the patient’s
psychotic symptoms disappeared and he was discharged on
day 17 on treatment with thyroxine 100 mg in the morning and
olanzapine 5 mg at night.
3. Discussion
Corticosteroid-induced psychiatric symptoms were first
described as “steroid psychosis” in 1950.7 Lewis et al reported
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experienced depression; this was followed by mania (28%),
psychosis (14%), delirium (10%), and mixed mood episodes
(8%).2 Psychiatric symptoms usually occur soon after the
initiation of steroid therapy. Hall et al8 reported a median onset
of 3e4 days, but rapid onsets and late onsets of up to 11 days
have also been reported.2,4,5
Corticosteroid-induced psychiatric syndromes are usually
managed by tapering off the steroid dose and treating the
psychiatric side-effects. After steroids are discontinued,
delirium may persist for a few days, mania for 3 weeks and
depression for 4 weeks. Half of all patients with steroid
psychosis improve within 4 days and the other half within 2
weeks.2,7 An open-label trial involving 12 outpatients with
mood symptoms from corticosteroid use found that those who
received olanzapine within 5 weeks showed significant
improvement in their psychiatric symptoms.9 Lithium,10 car-
bamazepine,11 and quetiapine12 have also been used success-
fully to treat steroid-induced manic symptoms based on
evidence from case reports.
The risk of steroid psychosis appears to be unrelated to age,
but there is a slight female predominance.2 A higher cortico-
steroid dose increases the risk of steroid psychosis. When 676
patients taking prednisone were evaluated during the Boston
Collaborative Drug Surveillance Project, the incidence of
steroid psychosis was 1.3% in patients receiving 40 mg per
day, 4.6% in those receiving 41e80 mg per day, and 18.4% in
those receiving >80 mg per day.3 Some authors have reported
cases of steroid psychosis at low doses of prednisolone.4,5 One
report showed that a daily dose of 2.5 mg prednisolone was
able to induce acute psychosis in a patient with Sheehan’s
syndrome.6 Patients with adrenal insufficiency are extremely
susceptible to steroid therapy and previous exposure to corti-
costeroids does not have a protective effect .One report
showed that six out of 17 cases of steroid-induced psychosis,
where there was previous exposure to corticosteroid therapy,
showed severe psychiatric symptoms during other courses of
corticosteroid therapy.2
Our patient had symptoms of adrenal insufficiency with
weakness and hyponatremia on his first and second ED visit. At
subsequent outpatient follow-up he received corticosteroids at
half the dose he was receiving at his second ED discharge. He
developed psychiatric symptoms after a second ED visit. He had
received a bolus of hydrocortisone 100 mg via intravenous
injection and a double dosage of steroids due to suspected adrenal
crisis at a third ED visit. He returned to the ED for a fourth time
with even more severe psychiatric symptoms. Analyzing his
clinical presentation, his symptoms of adrenal insufficiency with
weakness and diarrhea had improved since the third EDvisit. The
patient’s psychiatric symptoms then developed on day 4 after
starting corticosteroid therapy and became worse after intrave-
nous hydrocortisone and increased corticosteroid use. We
excluded the possibility of an adrenal insufficiency-related
mental change and stopped his steroid medication on day 8 and
began to administer an antipsychotic medication, olanzapine.
On day 9, he still had psychiatric symptoms and a diagnosis
of Hashimoto’s thyroiditis was made. This opened up thequestion as to whether the patient’s psychiatric symptoms
were related to Hashimoto’s encephalopathy (HE), which is
a condition associated with Hashimoto’s thyroiditis. The
criteria for HE are as follows: the presence of encephalopathy
together with elevated anti-thyroid antibodies in the absence of
a central nerves infection, tumor or stroke. HE has also been
referred to as an encephalopathy associated with thyroid
autoimmunity due to the typical response when it is treated
with steroids. The effects on the central nervous system are not
related to hypo- or hyperthyroidism. An elevated level of anti-
microsomal antibodies and/or anti-thyroglobulin antibodies is
an essential feature of HE, but the exact relationship between
the two is unclear. Two types of HE have been suggested: the
relapsing/remitting stroke-like type, and the diffuse progres-
sive type with psychosis and dementia. Chong at al searched
the Medline database and identified 85 patients with HE.13
Among these patients, 27% had stroke-like signs, 66% had
seizures, and 38% had psychosis. Diagnosis is based on the
clinical picture, the presence of anti-thyroid antibodies and the
exclusion of other causes. Cerebrospinal fluid analysis may
find elevated protein (78%) and an increased lymphocyte
count. The patient’s EEG is abnormal in nearly all cases
(98%), most commonly showing nonspecific slowing together
with focal spikes or sharp waves with seizures. MRIs of the
brain are usually normal, but may show atrophy and nonspe-
cific abnormalities in the subcortical white matter. Among
patients treated with glucocorticoids, 66 (96%) improved. The
optimal steroid dose has not been defined as yet, but oral
prednisone doses ranging from 50 to 150 mg per day have
been reported.14 High-dose intravenous steroids have also
been used. The symptoms typically improve or resolve over
a few months.15
The present patient had a high level of anti-thyroid anti-
bodies, abnormal EEG results and normal MRI findings, but
these do not allow a diagnosis of HE to be made. Two-and-a-
half months earlier, the patient had an episode of slow
response during consciousness, but his symptoms had
improved after normalization of the hyponatremia and treat-
ment with corticosteroids and thyroxine. During his second
ED visit, he had suffered from weakness and hyponatremia
and these improved after supplementation with corticosteroids
and thyroxine at the endocrine clinic during follow up. These
two episodes were clinically related to the hyponatremia. At
the third ED visit, psychiatric symptoms developed and pro-
gressed after he received a 100 mg hydrocortisone injection.
His psychiatric symptoms did not follow the clinical course of
stroke-like or diffuse progressive-type HE. If the patient had
HE, his psychiatric symptoms should have improved after
high doses of corticosteroids. However, in this case we
believed his psychiatric symptoms showed a temporal rela-
tionship to corticosteroid use. As a result, we did not continue
the high-dose corticosteroid therapy and in fact eventually
ceased corticosteroid use altogether. When we re-
administered prednisolone 5 mg per day on day 12, the
patient’s agitation recurred on day 13 and persisted even at
a dose of 2.5 mg per day. His corticosteroids were dis-
continued again and 2 days later he was discharged from our
124 S.-L. Chao et al. / Journal of Acute Medicine 2 (2012) 121e124ED without any psychiatric symptoms. A diagnosis of steroid
psychosis was made finally.
4. Conclusion
It can be seen from this case that emergency physicians
cannot always make a diagnosis based on laboratory tests and
image studies. With this case, we encountered a situation
where the question was whether or not give corticosteroids to
a delirious patient with adrenal insufficiency and Hashimoto’s
thyroiditis. We collected clinical information, identified
a temporal relation between the symptoms and corticosteroid
therapy, and then analyzed the different presentation of mental
change in terms of steroid psychosis, adrenal insufficiency,
and HE. We made a decision to stop corticosteroid use and this
finally allowed a diagnosis of steroid psychosis to be made.
Funding and conflicts of interest
None.
References
1. Brown ES, Chandler PA. Mood and cognitive changes during systemic corti-
costeroid therapy. Prim Care Companion J Clin Psychiatry. 2001;3:17e21.
2. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of
14 cases and a review of the literature. J Affect Disord. 1983;5:319e332.3. The Boston Collaborative Drug Surveillance Program. Acute adverse
reactions to prednisone in relation to dosage. Clin Pharmacol Ther.
1972;13:694e698.
4. Greeves JA. Rapid-onset steroid psychosis with very low dosage of
prednisolone. Lancet. 1984;1:1119e1120.
5. Sabharwal RK. Acute psychosis following single dose of prednisolone in
Sheehan’s syndrome. J Assoc Physicians India. 1987;35:806.
6. Hong SI, Cho DH, Kang HC, Chung DJ, Chung MY. Acute onset of
steroid psychosis with very low dose of prednisolone in Sheehan’s
syndrome. Endocr J. 2006;53:255e258.
7. Rome HP, Braceland FJ. Use of cortisone and ACTH in certain diseases:
psychiatric aspects. Proc Staff Meet Mayo Clin. 1950;25:495e497.
8. Hall R, Popkin M, Stickney S, Gardner E. Presentation of the steroid
psychoses. J Nerv Ment Dis. 1979;167:229e236.
9. Brown ES, Chamberlain W, Dhanani N, et al. An open-label trial of
olanzapine for corticosteroid-induced mood symptoms. J Affect Disord.
2004;83:277e281.
10. Merrill W. Case 35-1998: use of lithium to prevent corticosteroid induced
mania. N Engl J Med. 1999;340:1123.
11. Wada K, Yamada N, Yamauchi Y, Kuroda S. Carbamazepine treatment of
corticosteroid-induced mood disorder. J Affect Disord. 2001;65:315e317.
12. Siddiqui Z, Ramaswamy S, Petty F. Quetiapine therapy for corticosteroid-
induced mania. Can J Psychiatry. 2005;50:77e78.
13. Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome
or myth? Arch Neurol. 2003;60:164e171.
14. Kothbauer-Margreiter I, Sturzenegger M, Komor J, Baumgartner R,
Hess CW. Encephalopathy associated with Hashimoto thyroiditis: diag-
nosis and treatment. J Neurol. 1996;243:585e593.
15. Marshall GA, Doyle JJ. Long-term treatment of Hashimoto’s encepha-
lopathy. J Neuropsychiatry Clin Neurosci. 2006;18:14e20.
